For the fiscal year 2025, OptimizeRx Corp. (OPRX, Financial) anticipates its adjusted EBITDA to land between $13 million and $15 million. This projection highlights the company's financial strategy and expected growth trajectory in an uncertain market environment.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for OptimizeRx Corp (OPRX, Financial) is $10.39 with a high estimate of $16.00 and a low estimate of $6.00. The average target implies an upside of 12.97% from the current price of $9.20. More detailed estimate data can be found on the OptimizeRx Corp (OPRX) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, OptimizeRx Corp's (OPRX, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for OptimizeRx Corp (OPRX, Financial) in one year is $22.28, suggesting a upside of 142.17% from the current price of $9.2. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the OptimizeRx Corp (OPRX) Summary page.
OPRX Key Business Developments
Release Date: March 12, 2025
- Full Year Revenue: $92.1 million.
- Adjusted EBITDA: $11.7 million.
- Fourth Quarter Revenue: $32.3 million, up 14% from $28.4 million in Q4 2023.
- Gross Margin: Increased to 68.2% in Q4 2024 from 62.9% in Q4 2023.
- Operating Expenses: Decreased by $10.4 million year-over-year in Q4 2024.
- Net Loss: $0.1 million in Q4 2024, compared to $4.1 million in Q4 2023.
- Non-GAAP Net Income: $5.5 million or $0.30 per diluted share in Q4 2024.
- Adjusted EBITDA for Q4: $8.8 million, up from $5.8 million in Q4 2023.
- Cash and Short-term Investments: $13.4 million as of December 31, 2024.
- Debt Balance: $34.3 million after paying off $2.5 million of principal in Q4 2024.
- Average Revenue for Top 20 Pharmaceutical Manufacturers: $2.9 million, a 22% increase year-over-year.
- Net Revenue Retention Rate: 121%, up from 105% in the prior period.
- Revenue per FTE: $701,000, up from $586,000 in the prior year.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- OptimizeRx Corp (OPRX, Financial) exceeded its 2024 financial guidance with revenue of $92.1 million and adjusted EBITDA of $11.7 million.
- The company reported a significant gross margin increase from 62.9% in Q4 2023 to 68.2% in Q4 2024, driven by a favorable solution and channel partner mix.
- OptimizeRx Corp (OPRX) is transitioning to a subscription-based revenue model, which is expected to improve revenue predictability and margins.
- The company has a strong competitive edge with its large EHR prescription network and omnichannel technology platform, enhancing its ability to connect doctors and patients effectively.
- OptimizeRx Corp (OPRX) has seen a 25% average script lift in its 6-month programs, demonstrating strong brand engagement and measurable success.
Negative Points
- Despite improvements, OptimizeRx Corp (OPRX) reported a net loss of $0.1 million for Q4 2024, compared to a net loss of $4.1 million in Q4 2023.
- The company faces challenges with script abandonment, as approximately 50% of patients never fill their prescriptions at the pharmacy.
- OptimizeRx Corp (OPRX) is still in the early stages of transitioning to a Rule of 40 company, which is expected to take three to five years.
- The gross margin achieved in Q4 2024 is not expected to be sustainable throughout the year due to seasonal factors.
- The company is navigating a competitive environment, particularly with the integration of its DTC and HCP business models.
